The impact of nasal aspiration with an automatic device on upper and lower respiratory symptoms in wheezing children: a pilot case-control study

Table 5 Frequency of symptoms among patients using a DuoBaby nebulizer equipped (cases, n = 43) or not equipped (controls; n = 46) with a nasal aspirator stratified for the use of controller therapy (Inhaled Corticosteroid, ICS)

	Cases				Controls
	control therapy		no control therapy		control therapy		no control therapy
	n = 6		n = 37		n = 10		n = 36		p^b	p^c
	Median^a	IQR	Median^a	IQR	Median^a	IQR	Median^a	IQR	p^b	p^c
Nasal symptoms in the last 24 h	40.4	(30.8–74.9)	23.2	(13.3–41.2)	54.2	(49.3–57.9)	39.7	(24.9–58.5)	0.020	0.011
Bronchial symptoms in the last 24 h	40.6	(39.6–56.1)	20.8	(12.5–32.3)	34.6	(27.8–50.4)	29.7	(15–50.1)	0.035	0.031

^aMedian (IQR) of the percentages of days with symptoms calculated at individual level (see method for definition)
^bp-value for cases vs controls from linear regression adjusted for control therapy
^cMann Whitney U test was used to compare quantitative not normally distributed variables between cases vs controls groups (eliminating subjects with control therapy)
No statistical differences in subjects with control therapy between cases vs controls

ISSN: 1824-7288